Prepared by Dr. Michael Brown, CFA, Director of US Markets | Reviewed by Sofia Chen, Lead Editor | Report ID: IGEMINI-3BE7A970-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns is spacex publicly traded stock a Cautiously Constructive outlook for the next quarter. Key drivers include a P/E of 23.02x, 11.3% revenue expansion, and an RSI of 28 suggesting a neutral-bullish phase. We define critical support at $13356 and resistance at $16324.
Rating: Overweight | Target Price: $17362.8 | Next Earnings: Jun 05
Download Full PDF Report
Bollinger Bands contracted to the 15th percentile, signaling a breakout. A close above $17066 would be bullish.
RSI at 28 indicates a neutral-bearish state. Historical backtests suggest a +6.4% move within 10 sessions.
EPS of $644.66 reveals resilient earnings quality. DuPont analysis highlights asset turnover as the key ROE driver.
With a market cap of $23.45B, is spacex publicly traded stock operates in Healthcare. P/E of 23.02x is backed by 11.3% growth.
Options skew is toward put at the 13504.4 strike, positioning for a directional move.
Beta of 1.83 suggests is spacex publicly traded stock is {beta_desc} volatile than the market, influencing hedging strategies.
Short float at 6.7% is below the sector average, reducing squeeze risk. Institutional ownership is 56%.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $14840 | $14098 |
| Market Cap | $23.45B | $23.45B |
| P/E Ratio | 23.02x | 19.6x |
| EPS (TTM) | $644.66 | $580.19 |
| Dividend Yield | 2.31% | 1.6% |
| Revenue Growth | 11.3% | 6.8% |
| Target Price | $17362.8 | - |
| Beta | 1.83 | 1.00 |